Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 9, 1998, Pages 2391-2398

  Walsh, Thomas J ^a,d   Yeldandi, Vijay ^b   McEvoy, Maureen ^a   Gonzalez, Corina ^a   Chanock, Stephen ^a   Freifeld, Alison ^a   Seibel, Nita I ^c   Whitcomb, Patricia O ^d   Jarosinski, Paul ^e   Boswell, Garry ^g   Bekersky, Ihor ^g   Alak, Ala ^g   Buell, Donald ^g   Barret, John ^f   Wilson, Wyndham ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX;

ADULT; AGED; ANTIFUNGAL ACTIVITY; ARTICLE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUTROPENIA; PRIORITY JOURNAL; RIGOR; URTICARIA;

EID: 0031716174     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.9.2391     Document Type: Article

References (30)

1. Adler-Moore, J. P., and R. T. Proffit. 1993. Development, characterization, efficacy, and mode of action of AmBisome, a unilamellar formulation of amphotericin B. J. Liposome Res. 3:429-450.
2. Alak, A., S. Moys, and I. Bekersky. 1996. A high-performance liquid chromatographic assay for the determination of amphotericin B serum concentrations after the administration of AmBisome, a liposomal amphotericin B formulation. Ther. Drug Monit. 18:602-609.
3. Arning, M., K. O. Kliche, A. H. Heer-Sonderhoff, and A. Wehmeier. 1995. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses 38:459-465.
4. Arning, M., A. H. Heer-Sonderhoff, A. Wehmeier, and W. Schnemer. 1995. Pulmonary toxicity during infusion of liposomal amphotericin B in two patients with acute leukemia. Eur. J. Clin. Mierobiol. Infect. Dis. 14:41-43.
5. Bekersky, I., and W. A. Colburn. 1981. Renal clearance of carprofen in the isolated perfused rat kidney. Drug Metab. Dispos. 9:25-29.
6. Boswell, G., and W. G. Rodkey. 1983. Pharmacokinetics of hemoglobin infusion, p. 139-147. In R. B. Bolin. R. P. Geyer, and G. J. Nemo (ed.), Advanes in blood substitute research. Alan R. Liss, Inc., New York N.Y.
7. Francis, P., J. W. Lee, A. Hoffman,J. Peter, A. Francesconi, J. Bacher, J. Shelhamer, P. Pizzo, and T. J. Walsh. 1994. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar lavage D-mannitol and galactomannan as markers of infection. J. Infect. Dis. 169:356-368.
8. Gallis, H. A., R. H. Drew, and W. W. Pickard. 1990. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 12:308-329.
9. Gondal, J. A., R. P. Swartz, and A. Rahman. 1989. Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob. Agents Chemother. 33:1544-1548.
10. Heinemann, V., B. Kahny, A. Debus, K. Wackholz, and U. Jehn. 1994. Pharmacokinetics of liposomal amphotericin B (AmBisome) versus other lipid-based formulations. Bone Marrow Transpl. 14(Suppl.):S8-S9
11. Hiemenz, J. W., and T. J. Walsh. 1996. Lipid formulates of amphotericin B: recent progress and future directions. Clin. Infect. Dis. 22:S133-S144.
12. Lawrence, R. M., P. D. Hoeprich, F. A. Jagdis, N. Monji, A. C. Huston, and C. P. Schaffner. 1980. Distribution of doubly radiolabelled amphotericin B methyl ester and amphotericin B in the non-human primate. Maccaca mulatta. J. Antimicrob. Chemother. 6:241-249.
13. P. A. Pizzo and T. J. Walsh. 1994. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob Agents Chemother. 38:713-718.
14. Levine, S. J., T. J. Walsh, A. Martinez, P. Eichacker, G. Lopez-Berestein, and C. Natanson. 1991. Hypoxemia, pulmonary hypertension, and depression of cardiac output as sequelae of liposomal amphotericin B infusion. Ann. Intern. Med. 114:664-666.
15. Louie, A., A. L. Baltch, M. A. Franke, R. P. Smith, and M. A. Gordon. 1994. Comparative capacity of four antifungal agents to stimulate murine macrophage to produce tumour necrosis factor alpha: an effect that is attenuated bv pentoxifylline, liposomal vesicles, and dexamethasone. J. Antimicrob. Chemother. 34:975-987.
16. Mehta, T., G. Lopez-Berestein, R. Hopfer, K. Mills, and R. L. Juliano. 1984. Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochem. Biophys. Acta 770:230-234.
17. Meunier, F., H. G. Prentice, and O. Ringden. ,1991. Liposomal amphotencin B (AmBisome): safety data from a phase II/III clinical trial. J. Antimicrob. Chemother. 28(Suppl. B):83-91.
18. Mills, W., R. Chopra, D. C. Linch, and A. H. Goldston, 1994. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-center experience of 133 episodes m 116 patients. Br. J. Haematol. 86:754-760.
19. Ng, T. T. C., and D. W. Denning. 1995. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections: evaluation of United Kingdom compassionate use data. Arch. Intern. Med. 155:1093-1098.
20. Pannuti, C., R. Gingrich, M. A. Pfaller, C. Kao, and R. P. Wenzel. 1992. Nosocomial pneumonia in patients having bone marrow transplant. Attributable mortality and risk factors. Cancer 69:2653-2662.
21. Perkins, W. R., S. R. Minchey, L. T. Boni, C. E. Swenson, M. C. Popescu, R. F. Pasternack, and A. S. Janoff. 1992. Amphotericin B phospholipid interactions responsible for reduced mammalian cell toxicity. Biochim. Biophys. Acta 1107:271-282.
22. Pittet, D., and R. P. Wenzel. 1995. Nosocomial bloodstream infections. Secular trends in rates, mortality, and contribution to total hospital deaths. Arch. Intern. Med. 155:1177-1184.
23. Proffitt, R. T., A. Satorius, S. M. Chiang, L. Sullivan, and J. P. Adler-Moor, 1991. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J. Antimicrob. Chemother. 28(Suppl. B): 19-61.
24. Ringden, O., F. Meunier, J. Tollemar, P. Ricci, S. Tura, E. Kuse, M. A. Viviani, N. C. Gorin, J. Klastersky, and P. Fenaux. 1991. Efficacy of amphotericin B encapsulated in liposome (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J. Antimicrob. Chemother. 28(Suppl. B):73-82.
25. Tollemar, J., O. Ringden, S. Andersson, B. Sundberg, P. Ljungman, and G. Tyden. 1993. Randomized double-Wind study of liposomal amphotericin B (AmBisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant. 12:577-582.
26. Tollemar, J., and O. Ringden. 1992. Early pharmacokinetic and clinical results from a noncomparative multicenter trial of amphotericin B encapsulated in a small unilamellar liposome (AmBisome) in rodents. Drug Investig. 4:232-238.
27. Van Etten, E. W. M., M. Otte-Lambillion, W. van Vianen, M. T. ten Kate, and I. A. J. M. Bakker-Woudenberg. 1995. Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans. J. Antimicrob. Chcmother. 35:509-519.
28. Walsh, T., D. Bodensteiner, J. Hiemenz, S. Thaler, R. Greenberg, C. Arndt, J. Hokenberg, C. Schwartz, P. Pappas, S. Dummer, R. Marsh, M. Schuster, N. Seibel, The Mycoses Study Group (MSG), and the Empirical Antifungal Study Group. 1997. A randomized, double-blind trial of AmBisome (liposomal amphotericin B) versus amphotericin B in the empirieal treatment of persistently febrile neutropenic patients, abstr. LM-W. p. 381. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
29. Walsh, T. J., J. Hiemenz, and E. Anaissie. 1996. Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients. Infect. Dis. Clin. N. Am. 10:365-400.
30. Wasan, K. M., M. G. Rosenblum, L. Cheung, and G. Lopez-Berestein. 1994. Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrob. Agents Chemother. 38:223-227.